Toxicity studies Test Methods and Aim of Study Acute Oral Toxicity To provide informati- on on health hazards likely to arise from a short-term exposure to Stalosan ® F by the oral route. Body weight Gained body weight Acute Dermal Toxicity Study To provide informati- on on health hazards likely to arise from a short-term exposure to Stalosan ® F by the dermal route. Acute Inhalation Toxicity Study To provide informati- on on health hazards likely to arise from a short-term exposure to Stalosan ® F by the inhalation route. Primary Eye Irritation Study To provide informa- tion on the irritation likely to arise from an instillation of Stalo- san ® F into the eye. Primary Skin Irritation Study To provide infor- mation on the skin irritation likely to arise from a single topical exposure to Stalo- san ® F. Gained body weight Gained body weight Gained body weight Gained body weight Dermal Sensitization Study To determine the potential for Stalo- san ® F to elicit a skin sensitization reaction. Gained body weight Results Conclusion Necropsy No gross abnor- malities were noted for any of the animals. No gross abnor- malities were noted for any of the animals. No gross abnor- malities were noted for any of the animals. No gross abnor- malities were noted for any of the animals. Not relevant Not relevant General evaluation All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irrita- tion, adverse phar- macologic effects or abnormal behaviour. All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irrita- tion, adverse phar- macologic effects or abnormal behaviour. All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irrita- tion, adverse phar- macologic effects or abnormal behaviour. All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irrita- tion, adverse phar- macologic effects or abnormal behaviour. All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irrita- tion, adverse phar- macologic effects or abnormal behaviour. All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irrita- tion, adverse phar- macologic effects or abnormal behaviour. The acute oral LD50 of Stalosan F is greater than 5,000 mg/kg of body weight. The single dose acute dermal LD50 of Stalosan F is greater than 5,000 mg/kg of body weight. The single dose acute dermal LD50 of Stalosan F is greater than 5,000 mg/kg of body weight. Stalosan F is classified as mildly irritating to the eye. Stalosan F is classified as non-irritating to the skin. Stalosan F is not considered to be a contact sensitizer.
Share
Print
Download PDF file
